Drugs / LY3202626
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03023826 | Jan → Apr 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02555449 | Sep → Nov 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02323334 | Dec 2014 → Feb 2016 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT03367403 | Dec 2017 → Dec 2020 | Alzheimer disease | Eli Lilly and Company | Completed | Met primary |
| Phase 2 | NCT02791191 | Jun 2016 → Jul 2018 | Alzheimer disease | Eli Lilly and Company | Terminated | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3202626 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02791191 ↗ |
| Route | Oral | “administered orally” NCT02323334 ↗ |